Deal overview
| Target | HIKMA PHARMACEUTICALS PLC |
|---|---|
| Bidder | INSTITUTIONAL INVESTORS |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Jun 22, 2020 |
| Abstract | On 22 July 2020, the German pharmaceutical group Boehringer Ingelheim Invest GmbH ("Boehringer Ingelheim") announced that it intended to sell approximately 28 million ordinary shares (an 11.51% stake) in Hikma Pharmaceuticals Plc ("Hikma") by way of an accelerated bookbuild offering to institutional investors. Concurrently with the placing, Hikma had committed to buy back ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
